Outcomes of screening for prostate cancer among men who use statins

JAMAVettenranta A, Murtola TJ, Raitanen J, et al. | January 24, 2022


According to findings, the benefits conferred by prostate-specific antigen (PSA)-based screening are not materially compromised by statin use. PSA–based prostate cancer screening was found to be linked with less overdiagnosis of low-risk cancer in statin users, with similar mortality outcomes as in nonusers.

  • In this post hoc subgroup analysis of a cohort of 78,606 men in the Finnish Randomized Study of Prostate Cancer Screening, researchers investigated if statin use was linked with outcomes of a randomized PSA-based prostate cancer screening intervention.

  • Participants received three invitations for PSA screening at 4-year intervals from 1996 to 2007 vs routine care.

  • In statin nonusers, there was increased prostate cancer incidence in relation to PSA screening (screening vs control, 11.2 vs 8.6 per 1,000 person-years); rate ratio [RR], 1.31), but no similar rise in incidence was seen in statin users (6.9 vs 5.9 per 1000 person-years; RR, 1.02).

  • In statin users, a lower incidence of low-risk (Gleason score 6) and localized tumors was observed, whereas detection of tumors with a Gleason score of 8 to 10 was similar.

  • Screening was linked with a lower incidence of metastatic tumors irrespective of statin use.

Read the full article on JAMA